Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia

NCT04303520 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine as lead sponsor.

NCT NCT04303520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04303520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia
Lead sponsor
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase
Phase 1
Overall status
Unknown status
Start date
May 3, 2018
Completion date
February 28, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd19-positive all